WASHINGTON--(BUSINESS WIRE)--As many as one million American women could avoid painful and unnecessary biopsies of the cervix and another estimated 170,000 could potentially be identified with cervical disease up to two years earlier, if technology developed by Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) was widely used, according to a presentation made by Dr. Leo B. Twiggs, professor in the Department of Obstetrics and Gynecology at the University of Miami, Miller School of Medicine, to The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting. The presentation was entitled Study Results of a New Test for Cervical Dysplasia: Potential Impact on Patient Management.
